Skip to content
Clinical Trials – home

Central Hospital Of Northern Pest Military Hospital

Verified siteinfo

Hungary Podmaniczky Utca 109, 1062 Budapest, Hungary

  • 33 trials recruiting
  • Type 2 diabetes mellitus · Colitis ulcerative · Acromegaly
  • Adults and children

About Specializations

Central Hospital Of Northern Pest Military Hospital in Budapest, Hungary specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Colitis ulcerative, Acromegaly, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of research in gastroenterology, focusing on innovative treatments for conditions such as ulcerative colitis and short bowel syndrome. The center's work in this field aims to improve patient outcomes through advanced therapeutic strategies.

  • Ulcerative Colitis
  • Short Bowel Syndrome

By exploring novel induction therapies and long-term safety profiles, the center contributes significantly to the understanding and management of these complex conditions.

Cardiology

Specializing in cardiology, the center conducts pioneering research on chronic heart failure and hypertrophic cardiomyopathy. These studies aim to enhance therapeutic approaches and improve quality of life for patients with cardiovascular diseases.

  • Chronic Heart Failure
  • Hypertrophic Cardiomyopathy

Through innovative trials, the center is advancing the understanding of heart failure management and myocardial structure impacts.

Oncology

The center is a leader in oncology research, focusing on advanced therapies for breast cancer and head and neck cancer. These efforts are directed towards improving survival rates and treatment efficacy.

  • Breast Cancer
  • Head and Neck Cancer

By evaluating novel drug combinations and targeted therapies, the center is at the cutting edge of cancer treatment advancements.

Endocrinology

In the field of endocrinology, the center focuses on conditions such as acromegaly and diabetes. Research here aims to develop safer and more effective treatment protocols for these chronic conditions.

  • Acromegaly
  • Diabetes

Through long-term safety studies and efficacy trials, the center is enhancing the therapeutic landscape for endocrine disorders.

Ophthalmology

The center's research in ophthalmology is focused on innovative treatments for macular degeneration and blepharoptosis. These studies aim to preserve and improve vision in affected individuals.

  • Macular Degeneration
  • Blepharoptosis

By evaluating new therapeutic agents, the center is contributing to the advancement of eye care and treatment options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Podmaniczky Utca 1091062 BudapestHungary
Recruiting now
33 trials
Conditions studied
58
Partner status
Verified site

More sites in BudapestHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

103 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:PF-07328948
  • Sponsor:Pfizer Inc.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.